Entering text into the input field will update the search result below

Mast Therapeutics' AIR001 shows positive effect in mid-stage pulmonary hypertension study; shares up 6%

Nov. 03, 2016 10:41 AM ETSavara Inc. (SVRA) StockBy: Douglas W. House, SA News Editor2 Comments
  • Nano cap Mast Therapeutics (MSTX +6%) perks up on average volume in response to its announcement of encouraging preliminary results from an open-label Phase 2 clinical trial assessing now-lead product candidate AIR001 for the treatment of pulmonary hypertension (PH). The data were published in the Journal of Clinical Investigation.
  • Interim data from 36 patients receiving AIR001 (sodium nitrite solution for intermittent inhalation) showed decreases in pulmonary, right atrial and pulmonary capillary wedge pressures. The company says the effects were most pronounced in patients with PH associated with heart failure with preserved ejection fraction (PH-HFpEF). It adds that this subgroup also showed the largest increase in pulmonary artery compliance.
  • AIR001 was well-tolerated with no significant safety signals. There were also no significant decreases in peripheral oxygen saturation nor increases in methemoglobin levels about the stopping criteria of 5%.
  • Nitrite is a vasodilator. It is recycled in the body to form nitric oxide (NO). Nitrite-mediated NO dilates blood vessels and reduces inflammation and unwanted cell growth.

Recommended For You

About SVRA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SVRA--
Savara Inc.